Comparative Pharmacology
Head-to-head clinical analysis: HALDOL SOLUTAB versus SONAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALDOL SOLUTAB versus SONAZINE.
HALDOL SOLUTAB vs SONAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Haloperidol is a typical antipsychotic that primarily antagonizes dopamine D2 receptors in the mesolimbic pathway, also blocking alpha-adrenergic, histamine H1, and muscarinic receptors.
Sonazine is an antipsychotic agent that blocks postsynaptic dopamine D2 receptors in the mesolimbic system, with additional antagonist activity at D1, alpha1-adrenergic, histaminergic H1, and muscarinic M1 receptors.
1 to 15 mg orally once daily (tablet or orally disintegrating tablet). For acute agitation, 2.5 to 10 mg intramuscularly every 1 to 8 hours. Maximum oral dose: 100 mg/day; maximum IM dose: 20 mg/day.
10-20 mg intramuscularly or intravenously every 4-6 hours as needed; maximum 100 mg/day.
None Documented
None Documented
Terminal elimination half-life averages 21 hours (range 12-38 hours) in healthy adults; clinically significant for once-daily dosing.
Terminal elimination half-life: 24-36 hours; clinical context: allows once-daily dosing, steady state achieved in 5-7 days, prolongation in elderly or hepatic impairment
Renal (approximately 30-40% as metabolites, <1% unchanged); biliary/fecal (approximately 15-20%); significant enterohepatic recirculation.
Renal (70-80% as metabolites, <1% unchanged); fecal (15-20% via biliary elimination)
Category C
Category C
Antipsychotic
Antipsychotic